A carregar...
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-...
Na minha lista:
| Publicado no: | J Lipids |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889852/ https://ncbi.nlm.nih.gov/pubmed/29770231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3179201 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|